Vedanta Biosciences News and Activities

View the org chart displaying its 34 main executives

Most searched biographies at Vedanta Biosciences

• Bernat Olle, Chief Executive Officer and Director
• Andrew Davis, Director
• Sue Dillon, Board Member

Create your alert
to follow the executive moves at Vedanta Biosciences.

Vedanta Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Vedanta Biosciences

• Vedanta Biosciences Completes $68 Million Series D Financing :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC) :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at Upcoming Investor Conferences :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020 :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients :: Vedanta Biosciences, Inc.
• View more press releases Close

Social media about Vedanta Biosciences

• Vedanta Biosciences on Wikipedia, Google News & Yahoo Finance
• Vedanta Biosciences on LinkedIn, X (Twitter) & YouTube